Plasmonically Enhanced Microarray Immunoassay for High‐Sensitivity Monitoring of Heart Failure
Advanced Materials · 11.11.2026
DOI: 10.1002/adma.75631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 11.11.2026. Verfasst von Daria Semeniak und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Foundation, NIH HHS, Gordon and Betty Moore Foundation.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Point‑of‑care testing (POCT) demands diagnostic platforms that pair high analytical sensitivity with compact, low‑cost readout hardware, yet fluorescence‑based immunoassays face a fundamental tradeoff between detector cost and detection performance. Plasmonic nanocavities—such as metal–dielectric–metal nanopatch antennas—offer a powerful signal‑amplification strategy by dramatically enhancing fluorophore emission, enabling sensitive fluorescence detection with inexpensive optics. Here, we introduce a plasmonically enhanced fluorescence microarray immunoassay that integrates nanopatch antennas for high‑sensitivity, low‑cost quantification of key heart‑failure biomarkers, NT‑proBNP, NGAL, and galectin‑3, using a custom smartphone‑based detector. The nanopatch antennas yield up to 485‑fold fluorescence enhancement enabling quantitative and multiplexed detection with limits of detection of 0.055, 3.932, and 0.864 ng/mL, respectively. Analysis of NT‑proBNP–positive human samples shows strong correlation with clinically validated assays, demonstrating the potential of this plasmonically enhanced platform to deliver high‑performance heart‑failure biomarker monitoring at low cost in resource‑limited and point‑of‑care settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
- Department of Electrical and Computer Engineering, Duke University, Durham, North Carolina, USA.
- Division of Cardiology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
- Niels Bohr Institute, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Daria Semeniak, Deniz Acil, Daniela F Cruz, Cassio M Fontes, Brooke E Silverstein, G Michael Felker, Maiken H Mikkelsen, Ashutosh Chilkoti
Förderung
- Novo Nordisk Foundation
- NIH HHS
- Gordon and Betty Moore Foundation
- Novo Nordisk Fonden
- National Institutes of Health
Zitieren
APA
Semeniak, D., Acil, D., Liu, J., Cruz, D. F., Fontes, C. M., Li, C., Silverstein, B. E., Felker, G. M., Hucknall, A. M., Mikkelsen, M. H., & Chilkoti, A. (2026). Plasmonically Enhanced Microarray Immunoassay for High‐Sensitivity Monitoring of Heart Failure. Advanced Materials. https://doi.org/10.1002/adma.75631
Vancouver
Semeniak D, Acil D, Liu J, Cruz DF, Fontes CM, Li C, et al. Plasmonically Enhanced Microarray Immunoassay for High‐Sensitivity Monitoring of Heart Failure. Advanced Materials. 2026. doi:10.1002/adma.75631
BibTeX
@article{Semeniak2026,
author = {Semeniak, Daria and Acil, Deniz and Liu, Jason and Cruz, Daniela F and Fontes, Cassio M and Li, Chengyang and Silverstein, Brooke E and Felker, G Michael and Hucknall, Angus M and Mikkelsen, Maiken H and Chilkoti, Ashutosh},
title = {Plasmonically Enhanced Microarray Immunoassay for High‐Sensitivity Monitoring of Heart Failure},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.75631}
}
EUVIMED